{"pmid":32453903,"title":"Efficacy of therapeutic plasma exchange in severe COVID-19 patients.","text":["Efficacy of therapeutic plasma exchange in severe COVID-19 patients.","Coronavirus disease 2019 (COVID-19) could lead to a sharp increase in the levels of inflammatory cytokines. We report the efficacy of therapeutic plasma exchange in severe COVID-19 patients with acute respiratory distress syndrome. The results suggested TPE could be used as a strategy to attenuate circulating cytokines and inflammatory mediators.","Br J Haematol","Zhang, Li","Zhai, Hui","Ma, Shasha","Chen, Jiasheng","Gao, Yu","32453903"],"abstract":["Coronavirus disease 2019 (COVID-19) could lead to a sharp increase in the levels of inflammatory cytokines. We report the efficacy of therapeutic plasma exchange in severe COVID-19 patients with acute respiratory distress syndrome. The results suggested TPE could be used as a strategy to attenuate circulating cytokines and inflammatory mediators."],"journal":"Br J Haematol","authors":["Zhang, Li","Zhai, Hui","Ma, Shasha","Chen, Jiasheng","Gao, Yu"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32453903","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/bjh.16890","keywords":["coronavirus disease 2019 (covid-19)","cytokine storm","inflammatory parameters","oxygenation parameters","therapeutic plasma exchange"],"topics":["Treatment"],"weight":1,"_version_":1667881798356434944,"score":9.490897,"similar":[{"pmid":32391669,"title":"[Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab].","text":["[Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab].","OBJECTIVE: To observe the clinical effect of plasma exchange and tocilizumab in treatment of patients with severe coronavirus disease 2019 (COVID-19). METHODS: Six patients with severe COVID-19 admitted in First Affiliated Hospital of Bengbu Medical College from January 25 to February 25, 2020. Three patients were treated with plasma exchange and three patients were treated with tocilizumab. The effect on excessive inflammatory reaction of plasma exchange and tocilizumab was observed. RESULTS: The C-reactive protein (CRP) and IL-6 levels were significantly decreased and the lymphocyte and prothrombin time were improved in 3 patients after treatment with plasma exchange; while inflammation level was not significantly decreased, and lymphocyte and prothrombin time did not improve in 3 patients treated with tocilizumab. CONCLUSIONS: For severe COVID-19 patients with strong inflammatory reaction, plasma exchange may be preferred.","Zhejiang Da Xue Xue Bao Yi Xue Ban","Luo, Song","Yang, Lijuan","Wang, Chun","Liu, Chuanmiao","Li, Dianming","32391669"],"abstract":["OBJECTIVE: To observe the clinical effect of plasma exchange and tocilizumab in treatment of patients with severe coronavirus disease 2019 (COVID-19). METHODS: Six patients with severe COVID-19 admitted in First Affiliated Hospital of Bengbu Medical College from January 25 to February 25, 2020. Three patients were treated with plasma exchange and three patients were treated with tocilizumab. The effect on excessive inflammatory reaction of plasma exchange and tocilizumab was observed. RESULTS: The C-reactive protein (CRP) and IL-6 levels were significantly decreased and the lymphocyte and prothrombin time were improved in 3 patients after treatment with plasma exchange; while inflammation level was not significantly decreased, and lymphocyte and prothrombin time did not improve in 3 patients treated with tocilizumab. CONCLUSIONS: For severe COVID-19 patients with strong inflammatory reaction, plasma exchange may be preferred."],"journal":"Zhejiang Da Xue Xue Bao Yi Xue Ban","authors":["Luo, Song","Yang, Lijuan","Wang, Chun","Liu, Chuanmiao","Li, Dianming"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32391669","source":"PubMed","week":"202020|May 11 - May 17","e_drugs":["tocilizumab"],"topics":["Treatment"],"weight":1,"_version_":1666528580041965570,"score":137.28363},{"pmid":32431755,"pmcid":"PMC7220573","title":"The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the \"cytokine storm\" in COVID-19 patients: a hypothesis.","text":["The novel immunomodulatory biologic LMWF5A for pharmacological attenuation of the \"cytokine storm\" in COVID-19 patients: a hypothesis.","Background: A common complication of viral pulmonary infections, such as in the ongoing COVID-19 pandemic, is a phenomenon described as a \"cytokine storm\". While poorly defined, this hyperinflammatory response results in diffuse alveolar damage. The low molecular weight fraction of commercial human serum albumin (LMWF5A), a novel biologic in development for osteoarthritis, demonstrates beneficial in vitro immunomodulatory effects complimentary to addressing inflammation, thus, we hypothesize that LMWF5A could improve the clinical outcomes of COVID-19 by attenuating hyperinflammation and the potential development of a cytokine storm. Presentation of the hypothesis: A variety of human in vitro immune models indicate that LMWF5A reduces the production of pro-inflammatory cytokines implicated in cytokine storm associated with COVID-19. Furthermore, evidence suggests LMWF5A also promotes the production of mediators required for resolving inflammation and enhances the barrier function of endothelial cultures. Testing the hypothesis: A randomized controlled trial, to evaluate the safety and efficacy of nebulized LMWF5A in adults with Acute Respiratory Distress Syndrome (ARDS) secondary to COVID-19 infection, was developed and is currently under review by the Food and Drug Administration. Implications of hypothesis: If successful, this therapy may attenuate the cytokine storm observed in these patients and potentially reduce mortality, increase ventilation free days, improve oxygenation parameters and consequently lessen the burden on patients and the intensive care unit. Conclusions: In conclusion, in vitro findings suggest that the immunomodulatory effects of LMWF5A make it a viable candidate for treating cytokine storm and restoring homeostasis to the immune response in COVID-19.","Patient Saf Surg","Thomas, Gregory","Frederick, Elizabeth","Hausburg, Melissa","Goldberg, Laura","Hoke, Marshall","Roshon, Michael","Mains, Charles","Bar-Or, David","32431755"],"abstract":["Background: A common complication of viral pulmonary infections, such as in the ongoing COVID-19 pandemic, is a phenomenon described as a \"cytokine storm\". While poorly defined, this hyperinflammatory response results in diffuse alveolar damage. The low molecular weight fraction of commercial human serum albumin (LMWF5A), a novel biologic in development for osteoarthritis, demonstrates beneficial in vitro immunomodulatory effects complimentary to addressing inflammation, thus, we hypothesize that LMWF5A could improve the clinical outcomes of COVID-19 by attenuating hyperinflammation and the potential development of a cytokine storm. Presentation of the hypothesis: A variety of human in vitro immune models indicate that LMWF5A reduces the production of pro-inflammatory cytokines implicated in cytokine storm associated with COVID-19. Furthermore, evidence suggests LMWF5A also promotes the production of mediators required for resolving inflammation and enhances the barrier function of endothelial cultures. Testing the hypothesis: A randomized controlled trial, to evaluate the safety and efficacy of nebulized LMWF5A in adults with Acute Respiratory Distress Syndrome (ARDS) secondary to COVID-19 infection, was developed and is currently under review by the Food and Drug Administration. Implications of hypothesis: If successful, this therapy may attenuate the cytokine storm observed in these patients and potentially reduce mortality, increase ventilation free days, improve oxygenation parameters and consequently lessen the burden on patients and the intensive care unit. Conclusions: In conclusion, in vitro findings suggest that the immunomodulatory effects of LMWF5A make it a viable candidate for treating cytokine storm and restoring homeostasis to the immune response in COVID-19."],"journal":"Patient Saf Surg","authors":["Thomas, Gregory","Frederick, Elizabeth","Hausburg, Melissa","Goldberg, Laura","Hoke, Marshall","Roshon, Michael","Mains, Charles","Bar-Or, David"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32431755","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1186/s13037-020-00248-4","keywords":["acute lung injury","acute respiratory distress syndrome","barrier function","covid-19","cytokine storm","lmwf5a","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667342288238411777,"score":117.16083},{"pmid":32413619,"title":"beta-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects - Implications for coronavirus disease (COVID-19) immunotherapies.","text":["beta-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects - Implications for coronavirus disease (COVID-19) immunotherapies.","Coronavirus pneumonia is accompanied by rapid virus replication, where a large number of inflammatory cell infiltration and cytokine storm may lead to acute lung injury, acute respiratory distress syndrome (ARDS) and death. The uncontrolled release of pro-inflammatory cytokines, including interleukin (IL)-1beta and IL-6, is associated with ARDS. This constituted the first study to report on the variability in physicochemical properties of beta-glucans extracts from the same edible mushroom Lentinus edodes on the reduction of these pro-inflammatory cytokines and oxidative stress. Specifically, the impact on the immunomodulatory and cytoprotective properties of our novel in 'house' (IH-Lentinan, IHL) and a commercial (Carbosynth-Lentinan, CL) Lentinan extract were investigated using in vitro models of lung injury and macrophage phagocytosis. CL comprised higher amounts of alpha-glucans and correspondingly less beta-glucans. The two lentinan extracts demonstrated varying immunomodulatory activities. Both Lentinan extracts reduced cytokine-induced NF-kappaB activation in human alveolar epithelial A549 cells, with the IHL extract proving more effective at lower doses. In contrast, in activated THP-1 derived macrophages, the CL extract more effectively attenuated pro-inflammatory cytokine production (TNF-alpha, IL-8, IL-2, IL-6, IL-22) as well as TGF-beta and IL-10. The CL extract attenuated oxidative stress-induced early apoptosis, while the IHL extract attenuated late apoptosis. Our findings demonstrate significant physicochemical differences between Lentinan extracts, which produce differential in vitro immunomodulatory and pulmonary cytoprotective effects that may also have positive relevance to candidate COVID-19 therapeutics targeting cytokine storm.","Sci Total Environ","Murphy, Emma J","Masterson, Claire","Rezoagli, Emanuele","O'Toole, Daniel","Major, Ian","Stack, Gary D","Lynch, Mark","Laffey, John G","Rowan, Neil J","32413619"],"abstract":["Coronavirus pneumonia is accompanied by rapid virus replication, where a large number of inflammatory cell infiltration and cytokine storm may lead to acute lung injury, acute respiratory distress syndrome (ARDS) and death. The uncontrolled release of pro-inflammatory cytokines, including interleukin (IL)-1beta and IL-6, is associated with ARDS. This constituted the first study to report on the variability in physicochemical properties of beta-glucans extracts from the same edible mushroom Lentinus edodes on the reduction of these pro-inflammatory cytokines and oxidative stress. Specifically, the impact on the immunomodulatory and cytoprotective properties of our novel in 'house' (IH-Lentinan, IHL) and a commercial (Carbosynth-Lentinan, CL) Lentinan extract were investigated using in vitro models of lung injury and macrophage phagocytosis. CL comprised higher amounts of alpha-glucans and correspondingly less beta-glucans. The two lentinan extracts demonstrated varying immunomodulatory activities. Both Lentinan extracts reduced cytokine-induced NF-kappaB activation in human alveolar epithelial A549 cells, with the IHL extract proving more effective at lower doses. In contrast, in activated THP-1 derived macrophages, the CL extract more effectively attenuated pro-inflammatory cytokine production (TNF-alpha, IL-8, IL-2, IL-6, IL-22) as well as TGF-beta and IL-10. The CL extract attenuated oxidative stress-induced early apoptosis, while the IHL extract attenuated late apoptosis. Our findings demonstrate significant physicochemical differences between Lentinan extracts, which produce differential in vitro immunomodulatory and pulmonary cytoprotective effects that may also have positive relevance to candidate COVID-19 therapeutics targeting cytokine storm."],"journal":"Sci Total Environ","authors":["Murphy, Emma J","Masterson, Claire","Rezoagli, Emanuele","O'Toole, Daniel","Major, Ian","Stack, Gary D","Lynch, Mark","Laffey, John G","Rowan, Neil J"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32413619","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.scitotenv.2020.139330","keywords":["covid-19","cytokine storm","disease mitigation","immunomodulation","medicinal mushroom","beta-glucans"],"locations":["Carbosynth-Lentinan","Lentinan","Lentinan","Lentinan","beta-Glucan"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666897319252983808,"score":109.25615},{"pmid":32290839,"pmcid":"PMC7154566","title":"Why tocilizumab could be an effective treatment for severe COVID-19?","text":["Why tocilizumab could be an effective treatment for severe COVID-19?","A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome (ARDS), and even progressed into an intensive care unit (ICU) admission and died. The exploration for the mortality causes and advancing novel therapeutic development of severe COVID-19 is crucial at the moment. The biopsy samples analysis at autopsy suggested that increased alveolar exudate caused by aberrant host immune response and inflammatory cytokine storm probably impedes alveolar gas exchange and contributes to the high mortality of severe COVID-19 patients. Our research has identified that pathogenic T cells and inflammatory monocytes incite inflammatory storm with large amount of interleukin 6, therefore monoclonal antibody that targets the IL-6 pathways may potentially curb inflammatory storm. Moreover, Tocilizumab treatment that blocking IL-6 receptors showed inspiring clinical results including temperature returned to normal quickly and respiratory function improved. Therefore, we suggest that Tocilizumab is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality.","J Transl Med","Fu, Binqing","Xu, Xiaoling","Wei, Haiming","32290839"],"abstract":["A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome (ARDS), and even progressed into an intensive care unit (ICU) admission and died. The exploration for the mortality causes and advancing novel therapeutic development of severe COVID-19 is crucial at the moment. The biopsy samples analysis at autopsy suggested that increased alveolar exudate caused by aberrant host immune response and inflammatory cytokine storm probably impedes alveolar gas exchange and contributes to the high mortality of severe COVID-19 patients. Our research has identified that pathogenic T cells and inflammatory monocytes incite inflammatory storm with large amount of interleukin 6, therefore monoclonal antibody that targets the IL-6 pathways may potentially curb inflammatory storm. Moreover, Tocilizumab treatment that blocking IL-6 receptors showed inspiring clinical results including temperature returned to normal quickly and respiratory function improved. Therefore, we suggest that Tocilizumab is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality."],"journal":"J Transl Med","authors":["Fu, Binqing","Xu, Xiaoling","Wei, Haiming"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32290839","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1186/s12967-020-02339-3","keywords":["acute respiratory distress syndrome (ards)","covid-19","il-6","inflammatory storm","sars-cov-2","tocilizumab"],"link_comment_in":"32290847","e_drugs":["tocilizumab"],"topics":["Treatment"],"weight":1,"_version_":1666138494423007232,"score":99.05793},{"pmid":32297995,"title":"High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients.","text":["High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients.","Cytokines are important mediators of the inflammatory response, and during infection with SARS-CoV-2 it has been suggested that there is a cytokine storm syndrome. In this study, a meta-analysis was performed to investigate whether the IL-6/IFN-gamma ratio can help predict clinical severity in patients with COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Lagunas-Rangel, Francisco Alejandro","Chavez-Valencia, Venice","32297995"],"abstract":["Cytokines are important mediators of the inflammatory response, and during infection with SARS-CoV-2 it has been suggested that there is a cytokine storm syndrome. In this study, a meta-analysis was performed to investigate whether the IL-6/IFN-gamma ratio can help predict clinical severity in patients with COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Lagunas-Rangel, Francisco Alejandro","Chavez-Valencia, Venice"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32297995","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1002/jmv.25900","keywords":["hyperinflammation","inflammation","interferon","interleukin","cytokine storm","lung damage"],"topics":["Diagnosis"],"weight":1,"_version_":1666138493259087873,"score":95.606636}]}